|Statement||editors, Jonas T. Johnson, Mukund S. Didolkar.|
|Series||International congress series ;, no. 1009|
|Contributions||Johnson, Jonas T., Didolkar, Mukund S.|
|LC Classifications||RC280.H4 I47 1992|
|The Physical Object|
|Pagination||xvi, 997 p. :|
|Number of Pages||997|
|LC Control Number||93222090|
Dr. Jatin P. Shah has brought together contributing authors in a single volume that represents the head and neck management team at Memorial Sloan-Kettering Cancer Center. The strength of the volume is in its internal consistency of diagnostic approaches, therapeutic decisions, multidisciplinary treatment programs, and surgical techniques. An effort has also been made to Reviews: 1. An update on angiogenesis targeting in head and neck squamous cell carcinoma. Angiogenesis is an integral aspect of the growth and proliferation of solid tumors, including head and neck squamous cell carcinoma (HNSCC), and has potential implications in prognosis and treatment of both lo. Head and neck cancer is a highly malignant disease, and patient`s prognosis has not substantially improved during the recent decades. Recent advances in basic research have identified the genetic background underlying head and neck squammous cell carcinomas (HNSCCs) and the molecular pathways defining the biology of HNSCC-initiating cell. Head and Neck Cancer is the first, truly multi-disciplinary book in this field. The focus is the 2-part approach that any physician treating these patients must follow: maximize the chance for a cure while maintaining a strong emphasis on quality of by:
In laryngeal cancer, adding chemotherapy may allow organ preservation, improved local control, and improved survival. The treatment of advanced head and neck cancer requires an intensive, multispecialty approach by an experienced team of dedicated physicians, nurses, speech therapists, and nutritionists, among : $ Get this from a library! Head and neck cancer, volume III: proceedings of the Third International Conference on Head and Neck Cancer, San Francisco, July [Jonas T Johnson; Mukund S Didolkar;]. Patients with advanced squamous cell carcinoma of the head and neck who underwent PET-CT–guided surveillance after chemoradiation had overall survival rates similar to those of patients who underwent planned neck dissection and chemoradiation. But PET-CT imaging resulted in fewer operations and was more cost-effective than neck dissection. Background: We conducted an investigator-initiated, phase 3 randomized study to evaluate the efficacy and toxicity of addition of Nimotuzumab during concurrent chemoradiation in locally advanced squamous head and neck cancer (LASHNC).Methods: Adult subjects (age ≥ 18 years), with stage III-IV, LASHNC, Karnofsky performance status of ≥ 70 and adequate organ function Cited by: 2.
Clinical features and staging Differential diagnosis of a neck mass View in Chinese Evaluation of a neck mass in adults View in Chinese Human papillomavirus-associated head and neck cancer View in Chinese Management of late complications of head and neck cancer and its treatment View in Chinese Overview of the diagnosis and staging of head and neck cancer View in Chinese. Head and Neck Cancer • Developed world - 5% of all cancers • Developing world - 5th common cancer • Commonly mucosal squamous cell carcinoma • Historically smoking & alcohol related • 5yr overall survival % for locally advanced disease • Increasing incidence of HPV-associated oropharyngeal. Although most recurrences occur within 5 years of diagnosis, relapse can be seen at longer intervals. The incidences of second primary malignancies are fewer than after treatment of tumors at other head and neck sites.Circulating cancer-derived EBV-DNA in plasma is an established tumor marker for nasopharyngeal cancer, with a sensitivity of 96% and a specificity of . Head-and-neck squamous cell carcinoma (HNSCC) is the sixth most common malignancy worldwide, responsible for approximately half a million new cases every year .Approximately 60% of patients with HNSCC present with locally advanced, but non-metastatic disease (stage-III or IVA/B) at diagnosis.